{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:06:31Z","timestamp":1792073191907,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"DOI":"10.1007\/s40259-023-00578-6","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T20:32:21Z","timestamp":1675974741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study"],"prefix":"10.1007","author":[{"given":"Sun-Kyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kichul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Yang","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2827-0884","authenticated-orcid":false,"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-3367","authenticated-orcid":false,"given":"Hyoun-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"issue":"10055","key":"578_CR1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"9746","key":"578_CR2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094\u2013108.","journal-title":"Lancet"},{"issue":"9","key":"578_CR3","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","volume":"37","author":"TM Hunter","year":"2017","unstructured":"Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004\u20132014. Rheumatol Int. 2017;37(9):1551\u20137.","journal-title":"Rheumatol Int"},{"issue":"2","key":"578_CR4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123\u201330.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"578_CR5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/art.41597","volume":"73","author":"YM Chiu","year":"2021","unstructured":"Chiu YM, Lu YP, Lan JL, Chen DY, Wang JD. Lifetime risks, life expectancy, and health care expenditures for rheumatoid arthritis: a nationwide cohort followed up from 2003 to 2016. Arthritis Rheumatol. 2021;73(5):750\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"578_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102776","volume":"20","author":"FA Figus","year":"2021","unstructured":"Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4): 102776.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"578_CR7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/BOR.0000000000000703","volume":"32","author":"BR England","year":"2020","unstructured":"England BR, Hershberger D. Management issues in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2020;32(3):255\u201363.","journal-title":"Curr Opin Rheumatol"},{"key":"578_CR8","doi-asserted-by":"crossref","unstructured":"Kim JW, Suh CH. Systemic manifestations and complications in patients with rheumatoid arthritis. J Clin Med. 2020;9(6):2008.","DOI":"10.3390\/jcm9062008"},{"key":"578_CR9","doi-asserted-by":"crossref","unstructured":"Cassone G, Manfredi A, Vacchi C, Luppi F, Coppi F, Salvarani C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med. 2020;9(4):1082.","DOI":"10.3390\/jcm9041082"},{"issue":"3","key":"578_CR10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5152\/eurjrheum.2019.19036","volume":"6","author":"C Bes","year":"2019","unstructured":"Bes C. Comprehensive review of current diagnostic and treatment approaches to interstitial lung disease associated with rheumatoid arthritis. Eur J Rheumatol. 2019;6(3):146\u20139.","journal-title":"Eur J Rheumatol"},{"key":"578_CR11","doi-asserted-by":"crossref","unstructured":"Juge PA, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57(2):2000337.","DOI":"10.1183\/13993003.00337-2020"},{"issue":"11","key":"578_CR12","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, Conway R, Nikiphorou E. Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Rheumatology (Oxford). 2019;58(11):1900\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"578_CR13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00296-020-04773-4","volume":"41","author":"JK Dawson","year":"2021","unstructured":"Dawson JK, Quah E, Earnshaw B, Amoasii C, Mudawi T, Spencer LG. Does methoterxate cause progressive fibrotic interstitial lung disease? A systematic review. Rheumatol Int. 2021;41(6):1055\u201364.","journal-title":"Rheumatol Int"},{"issue":"4","key":"578_CR14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250339","volume":"16","author":"J Kur-Zalewska","year":"2021","unstructured":"Kur-Zalewska J, Kisiel B, Kania-Pud\u0142o M, T\u0142ustochowicz M, Chcia\u0142owski A, T\u0142ustochowicz W. A dose-dependent beneficial effect of methotrexate on the risk of interstitial lung disease in rheumatoid arthritis patients. PLoS ONE. 2021;16(4): e0250339.","journal-title":"PLoS ONE"},{"issue":"9","key":"578_CR15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/rheumatology\/kep050","volume":"48","author":"B Chikura","year":"2009","unstructured":"Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford). 2009;48(9):1065\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"578_CR16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","volume":"43","author":"C Roubille","year":"2014","unstructured":"Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613\u201326.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"578_CR17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4078\/jrd.2021.28.4.176","volume":"28","author":"J Kim","year":"2021","unstructured":"Kim J, Koh JH, Choi SJ, Jeon CH, Kwok S-K, Kim S-K, et al. KOBIO, the first web-based Korean biologics registry operated with a unified platform among distinct disease entities. J Rheum Dis. 2021;28(4):176\u201382.","journal-title":"J Rheum Dis"},{"issue":"9","key":"578_CR18","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"578_CR19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"578_CR20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"578_CR21","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/rheumatology\/keaa577","volume":"60","author":"CA Kelly","year":"2021","unstructured":"Kelly CA, Nisar M, Arthanari S, Carty S, Woodhead FA, Price-Forbes A, et al. Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study. Rheumatology (Oxford). 2021;60(4):1882\u201390.","journal-title":"Rheumatology (Oxford)"},{"key":"578_CR22","doi-asserted-by":"crossref","unstructured":"Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A. Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context. 2021;10:2020-8-8.","DOI":"10.7573\/dic.2020-8-8"},{"issue":"15","key":"578_CR23","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/archinte.168.15.1718","volume":"168","author":"LA Saketkoo","year":"2008","unstructured":"Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med. 2008;168(15):1718\u20139.","journal-title":"Arch Intern Med"},{"key":"578_CR24","doi-asserted-by":"crossref","unstructured":"Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30(160):210011.","DOI":"10.1183\/16000617.0011-2021"},{"issue":"9","key":"578_CR25","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","volume":"71","author":"JA Sparks","year":"2019","unstructured":"Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM, et al. Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol. 2019;71(9):1472\u201382.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"578_CR26","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","volume":"59","author":"C Fern\u00e1ndez-D\u00edaz","year":"2020","unstructured":"Fern\u00e1ndez-D\u00edaz C, Casta\u00f1eda S, Melero-Gonz\u00e1lez RB, Ortiz-Sanju\u00e1n F, Juan-Mas A, Carrasco-Cubero C, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology (Oxford). 2020;59(12):3906\u201316.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"578_CR27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10067-020-05227-9","volume":"40","author":"N Mena-V\u00e1zquez","year":"2021","unstructured":"Mena-V\u00e1zquez N, Godoy-Navarrete FJ, Manrique-Arija S, Aguilar-Hurtado MC, Romero-Barco CM, Ure\u00f1a-Garnica I, et al. Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis. Clin Rheumatol. 2021;40(1):133\u201342.","journal-title":"Clin Rheumatol"},{"key":"578_CR28","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, L\u00f8kke A, Bendstrup E, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76:1700\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"578_CR29","volume":"16","author":"CT Lin","year":"2021","unstructured":"Lin CT, Huang WN, Tsai WC, Chen JP, Hung WT, Hsieh TY, et al. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: analysis from the TRA Clinical Electronic Registry. PLoS ONE. 2021;16(4): e0250877.","journal-title":"PLoS ONE"},{"issue":"4","key":"578_CR30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","volume":"43","author":"I Flouri","year":"2014","unstructured":"Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43(4):447\u201357.","journal-title":"Semin Arthritis Rheum"},{"key":"578_CR31","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Aagaard D, L\u00f8rup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53: 151979.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"578_CR32","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford). 2019;58(2):e3-42.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"578_CR33","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.4049\/jimmunol.1900473","volume":"203","author":"EK Wu","year":"2019","unstructured":"Wu EK, Henkes ZI, McGowan B, Bell RD, Velez MJ, Livingstone AM, et al. TNF-induced interstitial lung disease in a murine arthritis model: accumulation of activated monocytes, conventional dendritic cells, and CD21(+)\/CD23(-) B cell follicles is prevented with anti-TNF therapy. J Immunol. 2019;203(11):2837\u201349.","journal-title":"J Immunol"},{"issue":"1","key":"578_CR34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3904\/kjim.2015.30.1.104","volume":"30","author":"BS Koo","year":"2015","unstructured":"Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med. 2015;30(1):104\u20139.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"578_CR35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/jcm9010277","volume":"9","author":"G Cassone","year":"2020","unstructured":"Cassone G, Manfredi A, Atzeni F, Venerito V, Vacchi C, Picerno V, et al. Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study. J Clin Med. 2020;9(1):277.","journal-title":"J Clin Med"},{"issue":"2","key":"578_CR36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","volume":"74","author":"M Neovius","year":"2015","unstructured":"Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74(2):354\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"578_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40259-019-00393-y","volume":"34","author":"HA Kim","year":"2020","unstructured":"Kim HA, Lee E, Lee SK, Park YB, Lee YN, Kang HJ, et al. Retention rate and safety of biosimilar CT-P13 in rheumatoid arthritis: data from the Korean College of Rheumatology Biologics Registry. BioDrugs. 2020;34(1):89\u201398.","journal-title":"BioDrugs"},{"issue":"1","key":"578_CR38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","volume":"22","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, et al. Drug retention of 7 biologics and tofacitinib in biologics-na\u00efve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2020;22(1):142.","journal-title":"Arthritis Res Ther"},{"key":"578_CR39","doi-asserted-by":"crossref","unstructured":"Kalyoncu U, Bilgin E, Erden A, Sat\u0131\u015f H, Tufan A, Tekg\u00f6z E, et al. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. Clin Exp Rheumatol. 2022;40(11):2071\u20137.","DOI":"10.21203\/rs.3.rs-903223\/v1"},{"key":"578_CR40","doi-asserted-by":"crossref","unstructured":"Tardella M, Di Carlo M, Carotti M, Ceccarelli L, Giovagnoni A, Salaffi F. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. Inflammopharmacology. 2022;30(3):705\u201312.","DOI":"10.1007\/s10787-022-00936-w"},{"issue":"3","key":"578_CR41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s11096-020-01171-5","volume":"43","author":"APM Gomides","year":"2021","unstructured":"Gomides APM, de Albuquerque CP, Santos ABV, B\u00e9rtolo MB, J\u00fanior PL, Giorgi RDN, et al. Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs \u201cin\u201d rheumatoid arthritis. Int J Clin Pharm. 2021;43(3):737\u201342.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"578_CR42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","volume":"48","author":"C Fern\u00e1ndez-D\u00edaz","year":"2018","unstructured":"Fern\u00e1ndez-D\u00edaz C, Loricera J, Casta\u00f1eda S, L\u00f3pez-Mej\u00edas R, Ojeda-Garc\u00eda C, Oliv\u00e9 A, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum. 2018;48(1):22\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"578_CR43","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/diagnostics11101794","volume":"11","author":"N Mena-V\u00e1zquez","year":"2021","unstructured":"Mena-V\u00e1zquez N, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Hidalgo Conde A, Arnedo D\u00edez de Los R\u00edos R, et al. Characteristics and predictors of progression interstitial lung disease in rheumatoid arthritis compared with other autoimmune disease: a retrospective cohort study. Diagnostics (Basel). 2021;11(10):1794.","journal-title":"Diagnostics (Basel)."},{"issue":"5","key":"578_CR44","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.55563\/clinexprheumatol\/h9tc57","volume":"39","author":"MS Fazeli","year":"2021","unstructured":"Fazeli MS, Khaychuk V, Wittstock K, Han X, Crocket G, Lin M, et al. Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk\/prognostic factors, and treatment landscape. Clin Exp Rheumatol. 2021;39(5):1108\u201318.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"578_CR45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3899\/jrheum.200863","volume":"48","author":"VL Kronzer","year":"2021","unstructured":"Kronzer VL, Huang W, Dellaripa PF, Huang S, Feathers V, Lu B, et al. Lifestyle and clinical risk factors for incident rheumatoid arthritis-associated interstitial lung disease. J Rheumatol. 2021;48(5):656\u201363.","journal-title":"J Rheumatol"},{"issue":"4","key":"578_CR46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457\u201365.","journal-title":"Expert Opin Drug Saf"},{"key":"578_CR47","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","volume":"10","author":"C Strehl","year":"2019","unstructured":"Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids- all-rounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744.","journal-title":"Front Immunol"},{"issue":"5","key":"578_CR48","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","volume":"50","author":"J Narv\u00e1ez","year":"2020","unstructured":"Narv\u00e1ez J, Robles-P\u00e9rez A, Molina-Molina M, Vicens-Zygmunt V, Luburich P, Ya\u00f1ez MA, et al. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease. Semin Arthritis Rheum. 2020;50(5):902\u201310.","journal-title":"Semin Arthritis Rheum"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00578-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00578-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00578-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:53:28Z","timestamp":1720709608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00578-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":48,"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00578-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"21 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All available data are reported in the manuscript and supplementary file.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"Ethics approval for the KOBIO registry was provided by the institutional review boards (IRBs) of all the 58 participating institutions. Ethics approval for this study and the use of KOBIO registry data was provided by the IRB of the researchers\u2019 affiliated hospitals (AJIRB-MED-21-450). This study was conducted in compliance with the principles of the Declaration of Helsinki. All the patients provided written informed consent to participate in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SKL: Contributed to method development and testing; drafted the work; data analysis and interpretation. JYJ and CHS: Contributed to study design and assessment plan; manuscript development. KS: Contributed to study design and assessment plan; data acquisition. JWK: Contributed to study design and assessment plan; manuscript conceptualization, development, and critically revised the manuscript. HAK: Contributed to study design and assessment plan; data acquisition, analysis, and interpretation; manuscript conceptualization, development, critically revised the manuscript, and authoring of manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}